Prospective, Single-Center, Randomized, Double-Blind, Clinical Trial for the Evaluation of Pain Associated With the Epidural Tuohy Needle Insertion With Prior Administration of 4% Lidocaine Patch or Intradermal Lidocaine Injection in Parturient Women Requesting Epidural for Analgesia Management
Ohio State University
Summary
Needle phobia is a barrier for receiving appropriate care during pregnancy and can lead to complications of the mother and fetus that could easily be avoided. Needle phobia can affect routine prenatal care, increase the demand for general anesthesia during c-section, and increase post-op pain. During epidural placement, providers use local anesthetic in various methods to numb the area where the needle will be inserted. Pain from these anesthetic administrations can increase needle phobia and their side effects. One use of local anesthetic is the lidocaine patch, and studies have shown it is effective in reducing pain level in patients \[6, Firmani\]. The transdermal lidocaine patch may lower the physical pain and mental effects of needle phobia in pregnant women and lower the side effects from that. Although lidocaine patch may take more time to numb the skin, a high number of expecting mothers will not require an epidural for labor analgesia right away. Therefore, administration of lidocaine patch might be an effective alternative. Pregnant women needing epidural placement will be randomized into three groups, the lidocaine patch group, intradermal anesthetic group, or use of both to determine the effectiveness of the lidocaine patch compared to the intradermal administration.
Eligibility
- Age range
- 18+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * o Age ³ 18 years old * Parturient women requesting neuraxial anesthesia/analgesia (epidural or CSE) for vaginal or Cesarean Delivery * Ability to consent in English Exclusion Criteria: * o Less than 30 minutes of lidocaine patch placement prior to epidural placement * Administration of opioids in the 4 hours before study enrollment * IV magnesium sulfate within the last 24 hours * Diabetes mellitus (Type I and II) * Neurocardiogenic signs or symptoms (e.g., dizziness, lightheadedness, bradycardia, and syncope) during IV cannulation * Cervical dilation \…